ICE方案治疗复发难治性非霍奇金弥漫大B细胞淋巴瘤临床观察

目的:观察ICE方案(异环磷酰胺IFO,卡铂CBP,依托泊苷VP-16)治疗复发/难治性非霍奇金弥漫大B细胞淋巴瘤(Non-hodgkin's lymphoma,NHL)的疗效及安全性。方法:20例经系统化疗后复发或进展的非霍奇金弥漫大B细胞淋巴瘤(DLBCL)患者,采用ICE方案化疗至少2周期,IFO 5 g/m2,第2天,持续24小时静脉输注,CBP按AUC=5,max 800 mg,第2天,静脉输注,VP-16.100 mg/m2,第1-3天,静脉输注。结果:完全缓解(complete response,CR)5例,部分缓解(partial response,PR)8例,疾病稳定(stable disease,SD)4例,疾病进展(progress disease,PD)3例,总有效率(overall response rate,ORR,CR+PR)65%,化疗副作用主要为骨髓抑制(Ⅰ、Ⅱ度6例,Ⅲ、Ⅳ度14例),其他不良反应包括胃肠道反应、粘膜损伤、肝肾毒性及脱发等均可耐受。结论:ICE方案可用于非霍奇金弥漫大B细胞淋巴瘤的二线化疗方案。

Recurrence of ICE Regimen for Refractory Non-Hodgkin's Diffuse Large B Cell Lymphoma in Clinical Observation

Objective:To evaluate the safety and efficacy of the ifosfamide (IFO) combined with carboplatin (CBP) and vepeside (VP-16) in the treatment of patients with relapsed or refractory non-Hodgkin''s lymphoma (NHL).Methods:Twenty patients with conformed relapsed or refractory Non-hodgkin''s lymphoma (NHL) were enrolled in this study. The chemotheraphy of regimen consisted of IFO(5 g/m2, day 2, continue 24 h), carboplatin(CBP=5, max 800 mg, day 2), and vepeside(1 00 mg/m2, day 1-3).Results:In the twenty cases,the complete response was in 5 cases, the partial response was in 8 cases, 4 cases was no change, 3 cases was progressive, and the oveall reponse rate (CR+PR) was 65%. Side effect of chemotherapy mainly manifest as bone marrow suppression, while other adverse reactions, including gastrointestinal reaction, mucosal injury, liver and kidney toxicity and hair loss, can be tolerated.Conclusion:ICE regimen can achieve a safety result in the treatment of relapsed or refractory non-Hodgkin''s lymphoma (NHL), and the toxicity was tolerable